The field of cancer immunotherapy has gained significant attention as a promising therapeutic approach, especially in light ...

Atlas H&E-TME delivers robust analyses at single-cell resolution in hours BERLIN and NEW YORK, Oct. 15, 2025 /PRNewswire/ -- Following successful early access pilots with leading biopharma partners, ...

Moderna Inc. (NASDAQ:MRNA) is one of the best high volume stocks to buy according to Wall Street analysts. On October 13, ...

A new mechanism explains how bacteria can drive treatment resistance in patients with oral and colorectal cancer.

Johns Hopkins scientists discovered a way to convert “immune-cold” tumors into “immune-hot” ones by activating key immune ...

RNA-4359 has advanced into the Phase 2 portion of the ongoing Phase 1/2 trial CAMBRIDGE, MA / ACCESS Newswire / October 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that clinical, safety and ...

Japanese scientists successfully eliminated cancer tumors using live bacteria, a new therapy that acts independently of the ...